Surgerii Robotics has launched the SMRAT multicenter randomized controlled trial (RCT), in partnership with top Chinese institutions including Ruijin Hospital, Shandong Provincial Hospital, and others. This landmark study compares single-port and multi-port robotic-assisted total mesorectal excision (TME) for rectal cancer—aiming to establish new clinical standards for ultra-minimally invasive surgery.
Powered by Surgerii’s proprietary snake-arm technology, the SHURUI® single-port surgical robot enables precise dissection and reconstruction through a single incision. The trial will evaluate key outcomes such as safety, recovery speed, oncological effectiveness, and patient quality of life.
SMRAT marks a milestone in evidence-based innovation. It also supports future inclusion in guidelines, national reimbursement, and international adoption.
Surgerii Robotics is advancing from innovation to leadership—bringing next-generation surgical solutions to patients worldwide.
Important Notes
The SHURUI Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has obtained the CE marking for urologic laparoscopic surgical procedures, gynecologic laparoscopic surgical procedures, general laparoscopic surgical procedures, and thoracoscopic surgical procedures. It is intended for use by trained surgeons in an operating room environment in accordance with the representative, specific procedures set forth in the User Manual.
Safety and Performance Information
Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other trademarks and may not be used without permission.
